In the published article, there was an error. The M and SD for the index value were incorrect.
A correction has been made to 3 Results, 3.3 Quality of life. This sentence previously stated:
“First, the descriptive part shows a statistically significant improvement of the index value from M = 0.90 (SD = 0.9) to M = 1.1 (SD = 1.2), second, the evaluation of the VAS improved from M = 67.3 (SD = 14.4) to 73.0 (SD = 13.4).”
The corrected sentence appears below:
“First, the descriptive part shows a statistically significant improvement of the index value from M = 0.81 (SD = 0.2) to M = 0.88 (SD = 0.1), second, the evaluation of the VAS improved from M = 67.3 (SD = 14.4) to 73.0 (SD = 13.4).”
In the published article, there was an error. The M value for QoL, EQ Index was incorrect.
A correction has been made to 4 Discussion, Paragraph 3. This sentence previously stated:
“The difference between the pre- and post-intervention groups was relatively small, with M = 2.4 (adherence), M = 5.7 (QoL, EQ VAS) and M = 0.2 (QoL, EQ Index), respectively.”
The corrected sentence appears below:
“The difference between the pre- and post-intervention groups was relatively small, with M = 2.4 (adherence), M = 5.7 (QoL, EQ VAS) and M = 0.07 (QoL, EQ Index), respectively.”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
drug safety, medication review, community pharmacy, interprofessional collaboration, polypharmacy, quality of life, antithrombotic medication
Citation
Hassanzadeh TE, Hohmann C and Culmsee C (2024) Corrigendum: Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy. Front. Pharmacol. 15:1507320. doi: 10.3389/fphar.2024.1507320
Received
07 October 2024
Accepted
22 October 2024
Published
31 October 2024
Volume
15 - 2024
Edited and reviewed by
Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa
Updates
Copyright
© 2024 Hassanzadeh, Hohmann and Culmsee.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tanja Elnaz Hassanzadeh, hassanzadeh@wir-machen-amts.de; Carsten Culmsee, culmsee@staff.uni-marburg.de
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.